Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS

Rice Hall James & Associates LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 300,791 shares of the company’s stock, valued at approximately $2,382,000. Rice Hall James & Associates LLC owned about 0.17% of Xeris Biopharma as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in XERS. Royal Bank of Canada boosted its stake in Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares during the last quarter. Millennium Management LLC grew its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after acquiring an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP bought a new stake in Xeris Biopharma during the 1st quarter valued at $170,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Up 3.9%

Xeris Biopharma stock opened at $8.85 on Wednesday. The firm has a market cap of $1.61 billion, a PE ratio of -80.45 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The firm’s 50 day moving average price is $8.00 and its two-hundred day moving average price is $6.84. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Insider Activity at Xeris Biopharma

In other news, Director John Johnson sold 15,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $91,350.00. Following the completion of the sale, the director directly owned 683,083 shares of the company’s stock, valued at $4,159,975.47. This trade represents a 2.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director owned 126,500 shares of the company’s stock, valued at $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 271,499 shares of company stock worth $2,038,917. 4.35% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

XERS has been the topic of several recent analyst reports. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma has an average rating of “Hold” and an average target price of $11.25.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.